Corcept Therapeutics (CORT) said late Monday it filed a new drug application to the US Food and Drug Administration for relacorilant to treat patients with endogenous hypercortisolism.
The application is based on positive results from the Grace trial and confirmatory evidence from the Phase 3 Gradient and long-term extension studies and a phase 2 study in hypercortisolism, the company said.
Hypercortisolism, or Cushing's syndrome, is caused by excessive activity of the hormone cortisol.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.